Case number# PHEH2015US003571, is an initial report received from a consumer on 18 Feb 2015, via a patient 
oriented program network for Gilenya guides (POP ID: POP00001382). This report refers to a 41-year-old female 
patient.
The patient s historical conditions were not reported. The patient s current condition included JC virus test positive. 
No concomitant medication was reported.
The patient received Gilenya (fingolimod) capsule for the treatment of multiple sclerosis from 01 May 2012 at an 
unknown dose and frequency and route was unknown. On 18 Feb 2015, 2 years, 9 months and 24 days after the 
first dose of the study medication the patient had "tested positive for the JC virus antibodies two years ago" (JC 
virus test positive). Patient neurologist has been monitoring it ever since. JC virus antibody levels are tested more 
recently a couple of months ago. The outcome of the event was reported as completely recovered on 18 Feb 2015.
Print Time: 07-JUN-2016 03:01 PM If a field is blank, there is no data for that field Page 291 of 549
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
Action taken with Gilenya was unknown at the time of this report.
Seriousness of the event was not reported. Seriousness assessment of tested positive for the JC virus antibodies 
two years ago was upgraded based on NVS-IME list. Causality of the event was not reported by the consumer.
Following an internal review done on 05 Mar 2015, for the data received on 18 Feb 2015, the following changes 
were done: The event tested positive for the JC virus antibodies two years ago was upgraded to serious.